



23rd March 2016

BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400001

National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block,  
Bandra Kurla Complex  
Bandra (East), Mumbai 400051

Scrip Code: 500674

Scrip Code: SANOFI

Dear Sirs,

Re: Press Release

We enclose herewith a Press Release, the contents of which are self-explanatory.

Thanking you,

SANOFI INDIA LIMITED

K.SUBRAMANI  
COMPANY SECRETARY

Encl:a/a



## **Dr. Vijay Mallya decides not to seek re-election as Director of Sanofi India Limited's Board at ensuing AGM**

**Mumbai - March 23, 2016** – Sanofi India Limited (SIL) today announced that its Chairman of the Board of Directors, Dr. Vijay Mallya has conveyed his decision to not seek re-election as a Director at the ensuing Annual General Meeting (AGM).

He became a Director of the Company (then called Hoechst Pharmaceuticals Limited) in December 1973 and has been Chairman of the Board since December 1983.

**Dr. Mallya**, in his message to the SIL Board of Directors, stated, "I have been privileged to preside over the Board of this Company, which started as Hoechst Pharmaceuticals Ltd. and to have participated in its phenomenal growth and prosperity over such an extraordinarily long period of time."

He further added, "Today, Sanofi India Limited is not only financially strong but with an impeccable track record. It is gratifying to me that the Company continues to serve needy patients in India with world-class medication whilst ensuring consistent returns to all stakeholders."

**Dr. Shailesh Ayyangar, Managing Director – SIL** stated, "The Board of Directors while accepting Dr. Mallya's decision, placed on record its deep appreciation of his exceptional service and leadership, firstly as a Director and subsequently as Chairman of the Board for over four decades."

Speaking about how Sanofi India has transformed in the recent past, Dr. Ayyangar further added, "In the last 10 years, Sanofi India Limited's total sales have grown from Rs. 800 crores to over Rs. 2000 crores. Its share price has gone up from Rs. 1,655/- in December 2005 to Rs. 4,358/- in December 2015, and the Market cap has almost tripled. Furthermore, the employee strength has grown from 1,500 to 3,700."

### ***New Independent Directors***

The Board of Directors has recommended to the shareholders that resolutions be passed at the ensuing Annual General Meeting to elect two new Independent Directors to the Board - **Aditya Narayan** and **Usha Thorat**, for a term of five years, from 30<sup>th</sup> April 2016.

Aditya Narayan, 64, has rich experience in industry for over 40 years. He served ICI Limited, now Akzo Nobel India Limited, for about 30 years across diverse functions and businesses. He was its Managing Director during 1996-2003 and then its non executive Chairman over 2003 - 2010. Over 2005-2009, he was the President and CEO of BHP Billiton India. He has also served as an Independent Director on a number of Boards. Presently, he is an Independent Director of Hindustan Unilever Limited since 2001, Linde India Limited since 2012 and Chambal Fertilizers and Chemicals Limited since 2015.

The SIL Board announced that it was its intention to appoint **Aditya Narayan** as the **next Chairman of the Board of Directors**, subject to his election as an Independent Director at the ensuing Annual General Meeting, and subject to the compliances laid down in the Articles of Association of the Company, the Companies Act, 2013 and the rules framed thereunder.

Usha Thorat, 66 joined the Reserve Bank of India (RBI) in 1972 after a Masters in Economics from Delhi School of Economics. She became Deputy Governor in 2005 and remained in this position till 2010. After stepping down from RBI, Ms. Usha Thorat was entrusted by the RBI to set up the Centre for Advanced Financial Research and Learning (CAFRAL) in banking and finance. She held charge as Director of CAFRAL from 2011 to 2014.

Currently, she is Chairperson of the Clearing Corporation of India Ltd. and also Chairperson of the Financial Benchmarks India (Pvt.) Ltd., both financial markets infrastructure companies. She is also active with a number of non -Governmental organizations including the Indian Cancer Society as trustee and Chairperson of the Governing and Advisory Council of the Cancer Cure Fund. She is a member of the Board of Governors of the Foundation for Ecological Security which works on issues of sustainability and equitable development and is a Trustee of the Impact India Foundation which works in the health space. She is also Vice President of the Bombay Natural History Society.

Sanofi India Limited (SIL) is listed on the BSE Limited and National Stock Exchange of India Limited. The parent company, Sanofi has 60.4% equity stake in this legal entity. The Company's portfolio includes pharmaceuticals and consumer healthcare products. Within pharmaceuticals, Sanofi India has a strong presence in diabetes, being the only Company with a balanced oral and insulin portfolio.

#### **About Sanofi**

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

#### **Sanofi Forward-Looking Statements**

*This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.*

---

#### **Contacts:**

##### **Sanofi India Media Relations**

Aparna Thomas

Tel. : +91 22 2803 2169

aparna.thomas@sanofi.com